AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Why ipatasertib Program Stalled
Karim Fizazi explains limited magnitude and lacking supportive endpoints led to ipatasertib program discontinuation.
Play episode from 48:10
Transcript
